Medical Oncology
The Medical Oncology Clinical Trials Team conducts clinical trials of new drugs for patients with cancer.
ADELE
The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.
AMT-151-01
This study will investigate the use of a new medicine called AMT-151 which may be used in the future as a possible treatment for advanced solid tumours.
ANZadapt
The research study is testing a new way of taking hormone tablets for prostate cancer. The new method is called ‘adaptive therapy,’ also known as a pause/restart strategy.
ASCERTAIN - Do you have newly diagnosed prostate cancer?
An Open-label, Randomised, Phase I, Multi-centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN)
CAPItello-281
The purpose of this study is to compare the effects, good or bad of an investigational product, capivasertib added to standard treatments in patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) and your cancer has low levels of a protein called PTEN (or “PTEN deficiency”).
ELAINE-3
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation.
GOLSEEK-2 - Golcadomide plus Rituximab for Follicular Lymphoma
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
INX-315-01
This study will investigate the use of a new medicine called INX-315 which may be used in the future as a possible treatment for advanced solid tumours.
IOS-1002-201 - administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002 administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors.
Keynote-B15
The trial is testing a potential new treatment for Muscle-invasive Bladder Cancer.